Product Description
A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this population. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20101189/)
Mechanisms of Action: GHRH Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Mexico | United States
Approved Indications: Lipodystrophy | Weight Loss
Known Adverse Events: Pain Unspecified | Erythema | Arthralgia | Myalgia | Edema
Company: Theratechnologies
Company Location: MONTREAL A8 H3A 1T8
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: HIV-Associated Lipodystrophy Syndrome|Hypopituitarism|Diabetic Retinopathy
Phase 3: Lipodystrophy|HIV Infections|HIV-Associated Lipodystrophy Syndrome
Phase 2: Type 2 Diabetes|Muscular Atrophy|Cognitive Dysfunction|Obesity, Abdominal|Parasomnias|Chronic Obstructive Pulmonary Disease|Wasting Syndrome|Traumatic Brain Injury|Cachexia|Wasting Disease, Chronic|Dwarfism, Pituitary|Hypopituitarism|Peripheral Nerve Injuries|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Fatty Liver Disease|HIV Infections
Phase 1: HIV Infections|Cognitive Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRIUMPH | P2 |
Not yet recruiting |
HIV Infections|Obesity, Abdominal |
2028-03-01 |
|
| IRB00110936-2 | P2 |
Recruiting |
Peripheral Nerve Injuries |
2025-12-01 |
|
| AAAR2634 | P4 |
Recruiting |
HIV-Associated Lipodystrophy Syndrome|Hypopituitarism |
2025-04-30 |
|
| R01DK114144 | P2 |
Active, not recruiting |
Fatty Liver, Alcoholic|Liver Diseases, Alcoholic|Obesity, Abdominal|Non-alcoholic Fatty Liver Disease |
2024-07-10 |